Document:

EX-10.12(b)

 Exhibit 10.12(b) 

ONCOTHYREON INC. 

AMENDMENT NO. 2 TO DIANA HAUSMAN OFFER LETTER 

This amendment (this “Amendment”) is made by and between Diana Hausman (“Executive”) and
Oncothyreon Inc., a Delaware corporation (the “Company” and, together with Executive, hereinafter collectively referred to as the “Parties”) on December 21, 2015. 

WITNESSETH: 

WHEREAS, the Parties previously entered into an offer letter dated July 6, 2009, as amended on December 3, 2009 (as amended,
the “Offer Letter”); and 
 WHEREAS, the Company and Executive desire to amend the Offer Letter to provide
Executive with increased severance benefits; 
 NOW, THEREFORE, for good and valuable consideration, Executive and the Company agree
that the Offer Letter is hereby further amended as follows: 
 1. Amendment to Offer Letter. Section 6 of the Offer Letter is
hereby amended and restated in its entirety to read as follows: 
  

	 	“6.	Severance: In the event your employment is terminated by the Company for any reason other than “Cause” (as defined below) you will be entitled to the following: 

 

	 	i)	lump sum payment of nine month’s base salary, less required withholding, and 

  

	 	ii)	lump sum payment of nine month’s equivalent of performance review bonus at target, less required withholding. 

Such payments will be made within sixty (60) days following your termination of employment. 

“Cause” for the purpose of this letter agreement shall include but not be limited to (i) willful engaging in illegal conduct or
gross misconduct that is injurious to the Company or an affiliated company, (ii) being convicted of, or entering a plea of nolo contendere or guilty to, a felony or a crime of moral turpitude; (iii) engaging in fraud,
misappropriation, embezzlement or any other act or acts of dishonesty resulting or intended to result directly or indirectly in a gain or personal enrichment to you at the expense of the Company or an affiliated company, (iv) material breach of
any written policies of the Company or an affiliated company, or (v) willful and continual failure substantially to perform your duties with the Company, which failure has continued for a period of at least 30 days after written notice by the
Company.” 
 2. Section 409A. Section 8 of the Offer Letter is hereby added as follows: 

 

	 	“8.	Section 409A: 

 i) Notwithstanding anything to the contrary in this letter agreement, no
benefits payable to you, if any, pursuant to this letter agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (together, the “Deferred
Payments”) will be payable until you have a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to you, if any, pursuant to this letter agreement that otherwise would be exempt from
Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until you have a “separation from service” within the meaning of Section 409A. 

 ii) Notwithstanding anything to the contrary in this letter agreement, if you are a
“specified employee” within the meaning of Section 409A at the time of your separation from service, then, if required, the Deferred Payments, which are otherwise due to you on or within the six (6) month period following your
separation from service, will accrue, to the extent required, during such six (6) month period and will become payable in a lump sum payment on the date six (6) months and one (1) day following the date of your separation from service
or the date of your death, if earlier. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this letter agreement is intended
to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 
 iii) Any amount paid under the letter
agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above. 

iv) Any amount paid under this letter agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant
to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred Payments for purposes of clause (i) above. “Section 409A Limit” will mean the lesser of two
(2) times: (i) your annualized compensation based upon the annual rate of pay paid to you during your taxable year preceding your taxable year of your termination of employment as determined under Treasury Regulation
Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal
Revenue Code for the year in which your employment is terminated. 
 v) The foregoing provisions are intended to comply with the requirements
of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. You and the Company
agree to work together in good faith to consider amendments to this letter agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual
payment to you under Section 409A.” 
 3. Full Force and Effect. To the extent not expressly amended hereby, the Offer
Letter shall remain in full force and effect. 
 4. Entire Agreement. This Amendment and the Offer Letter constitute the full and
entire understanding and agreement between the Parties with regard to the subjects hereof and thereof. This Amendment may be amended at any time only by mutual written agreement of the Parties. 

5. Counterparts. This Amendment may be executed in counterparts, all of which together shall constitute one instrument, and each of
which may be executed by less than all of the parties to this Amendment. 
 6. Governing Law. This Amendment will be governed by the
laws of the State of Washington (with the exception of its conflict of laws provisions). 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the date set
forth above. 
  

							
	COMPANY:	 		 	ONCOTHYREON INC.
			
		 		 	 /s/ Robert Kirkman

		 		 	By:	 	Robert Kirkman, M.D.
		 		 	Title:	 	Chief Executive Officer
			
	EXECUTIVE:	 		 	DIANA HAUSMAN
			
		 		 	 /s/ Diana Hausman

		 		 	Diana Hausman, M.D.EX-10.19

 Exhibit 10.19 
  

			
		  	 *  Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the
Securities Exchange Act of 1934, as amended.

 THIRD AMENDMENT TO PATENT LICENSE AGREEMENT 

between 

STC.UNM and ONCOTHYREON INC. 

THIS THIRD AMENDMENT TO PATENT LICENSE AGREEMENT (“Third Amendment”) is made effective as of October 13, 2015 (the
“Third Amendment Effective Date”) by and between STC.UNM (hereinafter referred to as “STC”), a New Mexico nonprofit corporation, with its principal office at 801 University Boulevard SE, Suite 101, Albuquerque, New Mexico
87106, and ONCOTHYREON INC. (hereinafter referred to as “Oncothyreon”), a Delaware corporation with a principal office at 2601 Fourth Avenue, Suite 500, Seattle, WA 98121. As of the Third Amendment Effective Date, in consideration
of the mutual covenants and promises herein contained, the parties agree as follows: 
 1. Background of Third Amendment. STC
and Oncothyreon are parties to a Patent License Agreement (STC Ref. No. 2013-0170) effective June 30, 2014, as amended on February 2, 2015 (the “First Amendment”) and September 15, 2015 (the “Second
Amendment”) (together, the “License Agreement”). The parties desire to enter into this Third Amendment to expand the scope of the License Agreement to cover certain additional patent applications and to clarify certain provisions of
the License Agreement. Capitalized terms in this Third Amendment, unless defined herein, shall have the meanings ascribed to such terms in the License Agreement. 

2. Amendment of Section 2.10. Section 2.10 of the License Agreement is hereby amended to read in its entirety as follows:

 The parties agree that all patents or patent applications on any inventions or discoveries covering or related to protocells that are:
(a) owned by STC, and (1) name the same Inventors as any of the Licensed Patents and (2) are developed pursuant to the Sponsored Research Agreement by and between the University and LICENSEE, dated as of July 14, 2014 as amended
(the “Sponsored Research Agreement”); or, (b) name the same Inventors as any of the Licensed Patents (including, for clarity, Principal Investigator, whether as the sole inventor or as a co-inventor with other Inventors of the
Licensed Patents or with LICENSEE’s employees or contractors) and cover subject matter conceived and/or reduced to practice by Principal Investigator in performance of the Research (whether solely by Principal Investigator or jointly with other
Inventors of the Licensed Patents or LICENSEE’s employees or contractors), to the extent STC is named as, or otherwise becomes, the commercialization manager pursuant to the MOU and/or the Letter Agreement for such patents or patent
applications referenced in this subsection (b), shall be added to this Agreement as a Licensed Patent and shall be subject to the terms and conditions of this Agreement, including the royalty obligations set out herein, at LICENSEE’s election
without the need for any further action by the parties upon 
  

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 	1	 	
		 		 	*Confidential Treatment Requested.

 
receipt by STC of LICENSEE’s notice of election, provided that LICENSEE shall pay to STC an amount equal to $[*] for each such Licensed Patent LICENSEE elects to add to this Agreement in
accordance with this Section 2.10, such payment to be made within thirty (30) days following receipt of STC’s invoice. The provisions of subsection (a) above shall apply notwithstanding anything to the contrary in
Section 7(c)(ii) of the Sponsored Research Agreement. STC will promptly notify LICENSEE of any such patent applications. For clarity, a patent or patent application shall be deemed to meet the “same Inventors” requirement under the
preceding subsections (a)(1) and (b) to the extent such patent or patent application names at least one (1) inventor that is an Inventor of any of the Licensed Patents (which may be the Principal Investigator) and does not name any other
inventor (i.e., other than an Inventor of any of the Licensed Patents) that is employed by the University of New Mexico or for whom STC otherwise serves as the commercialization manager with respect to the patent or patent application in question.
In addition, the parties agree that to the extent that STC owns any rights under patents and patent applications claiming any inventions or discoveries covering or related to protocells but that are not covered by subsections (a) or
(b) above, the parties agree to discuss in good faith adding such patents or patent applications as Licensed Patents under this Agreement. For clarity, nothing in this Agreement shall be construed to limit LICENSEE’s joint ownership rights
in and to any invention conceived or reduced to practice by Principal Investigator jointly with LICENSEE’s employees or contractors, or LICENSEE’s ability to claim or exploit, without any duty to account, any such joint ownership rights.

 3. Election Pursuant to Section 2.10. Pursuant to Section 2.10 of the License Agreement, the patent applications
identified on Schedule 1 attached hereto are hereby added to the License Agreement as additional Licensed Patents as of the Third Amendment Effective Date. In consideration for such addition, LICENSEE shall pay to STC an amount equal to $[*] (i.e.,
$[*] per patent application). This Section 3 shall constitute LICENSEE’s notice of election pursuant to Section 2.10 of the License Agreement with respect to the patent applications identified on Schedule 1. This Section 3 is
subject to Section 5 of this Third Amendment. 
 4. Additional Patent Application. The patent application identified on Schedule
2 attached hereto is hereby added to the License Agreement as an additional Licensed Patent as of the Third Amendment Effective Date, and shall be subject to the terms and conditions of the License Agreement, including the royalty obligations set
out therein. In consideration for such addition, LICENSEE shall pay to STC an amount equal to $[*]. This Section 4 is subject to Section 5 of this Third Amendment. 

5. Commercialization Agreement. LICENSEE acknowledges that the patent applications identified on Schedule 1 and Schedule 2 attached
hereto are owned jointly by STC and Sandia. Unless and until STC and Sandia enter into a Commercialization Agreement with respect to such patent applications, Sandia retains all rights of a joint patent owner with respect to such applications,
including the power to grant licenses with respect to such applications. Following execution of this Third Amendment, STC agrees to use commercially reasonable efforts to negotiate and execute a Commercialization Agreement with Sandia with respect
to such patent applications. Upon the execution of a Commercialization Agreement by STC and 
  

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 	2	 	
		 		 	*Confidential Treatment Requested.

 
Sandia with respect to any such patent application, such application shall be a Commercialization Agreement Licensed Patent under the License Agreement. STC shall notify LICENSEE of the execution
of each such Commercialization Agreement, and any limitations imposed by Sandia under the Commercialization Agreement, including any fields of use for which Sandia has retained the right to grant licenses. Upon the execution of a Commercialization
Agreement by STC and Sandia with respect to any such patent application, STC shall provide LICENSEE with a revised Exhibit A, reflecting the change of the applicable patent application to a Commercialization Agreement Licensed Patent under the
License Agreement. 
 6. Payment Terms. Following execution of this Third Amendment, STC shall invoice LICENSEE for the amounts due
to STC under Sections 3 and 4, and LICENSEE shall pay such amount to STC within thirty (30) days following receipt of such invoice. 

7. Updated Exhibit A. Exhibit A of the License Agreement is hereby replaced in its entirety with Exhibit A attached hereto. 

8. Ratification. Except as amended hereby, all other terms and conditions of the License Agreement are ratified and confirmed and
remain in full force and effect. 
 IN WITNESS WHEREOF, each of the parties has caused this Third Amendment to be executed by its
duly authorized representative on the respective dates entered below, effective as of the Third Amendment Effective Date. 
 [signature
page follows] 

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 	3	 	
		 		 	*Confidential Treatment Requested.

									
	 LICENSOR:

STC.UNM
	 		 	 LICENSEE:
 ONCOTHYREON
INC.

					
	By:	 	 /s/ Elizabeth J. Kuuttila
	 		 	By:	 	 /s/ Robert L. Kirkman

					
		 	Elizabeth J. Kuuttila	 		 	Printed Name:	 	 Robert L. Kirkman

		 	President & CEO	 		 	Title:	 	 President & CEO

					
	Date:	 	 10/31/15
	 		 	Date:	 	 10/13/15

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 	4	 	
		 		 	*Confidential Treatment Requested.

 SCHEDULE 1 

PATENT APPLICATIONS ADDED PURSUANT TO SECTION 2.10 

[*] 

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 		 	
		 		 	*Confidential Treatment Requested.

 SCHEDULE 2 

ADDITIONAL PATENT APPLICATION 

[*] 

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 		 	
		 		 	*Confidential Treatment Requested.

 EXHIBIT A 

LICENSED PATENTS 
 [*]

  

					
	 STC – Alpine Biosciences Third Amendment License No. 2013-0170

[*]
	 		 	
		 		 	
		 		 	*Confidential Treatment Requested.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]